These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 20491785)

  • 21. Antigen-presenting effects of effector memory Vγ9Vδ2 T cells in rheumatoid arthritis.
    Hu C; Qian L; Miao Y; Huang Q; Miao P; Wang P; Yu Q; Nie H; Zhang J; He D; Xu R; Chen X; Liu B; Zhang D
    Cell Mol Immunol; 2012 May; 9(3):245-54. PubMed ID: 22139198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
    Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
    Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
    Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
    J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
    Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
    Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
    Li Z; Peng H; Xu Q; Ye Z
    J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of cytotoxic T lymphocytes by CEA peptide-pulsed γδ T-cells isolated from patients with advanced cancer.
    Yamasaki A; Onishi H; Morisaki T; Katano M
    Anticancer Res; 2011 Jul; 31(7):2419-24. PubMed ID: 21873153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpaca (
    Fichtner AS; Karunakaran MM; Gu S; Boughter CT; Borowska MT; Starick L; Nöhren A; Göbel TW; Adams EJ; Herrmann T
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6697-6707. PubMed ID: 32139608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
    Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
    Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
    Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human γδ peripheral blood lymphocytes.
    DeBarros A; Chaves-Ferreira M; d'Orey F; Ribot JC; Silva-Santos B
    Eur J Immunol; 2011 Jan; 41(1):195-201. PubMed ID: 21182090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
    Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS
    Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
    Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
    Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.
    Thedrez A; Lavoué V; Dessarthe B; Daniel P; Henno S; Jaffre I; Levêque J; Catros V; Cabillic F
    PLoS One; 2013; 8(5):e63322. PubMed ID: 23717410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
    Kakimi K; Matsushita H; Masuzawa K; Karasaki T; Kobayashi Y; Nagaoka K; Hosoi A; Ikemura S; Kitano K; Kawada I; Manabe T; Takehara T; Ebisudani T; Nagayama K; Nakamura Y; Suzuki R; Yasuda H; Sato M; Soejima K; Nakajima J
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32948652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TCR repertoire analysis reveals phosphoantigen-induced polyclonal proliferation of Vγ9Vδ2 T cells in neonates and adults.
    Fichtner AS; Bubke A; Rampoldi F; Wilharm A; Tan L; Steinbrück L; Schultze-Florey C; von Kaisenberg C; Prinz I; Herrmann T; Ravens S
    J Leukoc Biol; 2020 Jun; 107(6):1023-1032. PubMed ID: 32064671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.
    Coscia M; Vitale C; Peola S; Foglietta M; Rigoni M; Griggio V; Castella B; Angelini D; Chiaretti S; Riganti C; Guarini A; Drandi D; Ladetto M; Bosia A; Foà R; Battistini L; Boccadoro M; Fournié JJ; Massaia M
    Blood; 2012 Oct; 120(16):3271-9. PubMed ID: 22932792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An optimized cultivation method for future
    Bold A; Gross H; Holzmann E; Knop S; Hoeres T; Wilhelm M
    Front Immunol; 2023; 14():1185564. PubMed ID: 37539052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
    Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
    J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.